Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2017

01-03-2017 | Translational Research and Biomarkers

Attenuated RND1 Expression Confers Malignant Phenotype and Predicts Poor Prognosis in Hepatocellular Carcinoma

Authors: Hisateru Komatsu, MD, Tomohiro Iguchi, MD, PhD, Takaaki Masuda, MD, PhD, Hidenari Hirata, MD, Masami Ueda, MD, Shinya Kidogami, MD, Yushi Ogawa, MD, Kuniaki Sato, MD, Qingjiang Hu, MD, Sho Nambara, MD, Tomoko Saito, MD, Shotaro Sakimura, MD, Ryutaro Uchi, MD, Shuhei Ito, MD, PhD, Hidetoshi Eguchi, MD, PhD, Keishi Sugimachi, MD, PhD, Hidetoshi Eguchi, MD, PhD, Yuichiro Doki, MD, PhD, Masaki Mori, MD, PhD, Koshi Mimori, MD, PhD

Published in: Annals of Surgical Oncology | Issue 3/2017

Login to get access

ABSTRACT

Background

The RND1 gene encodes a protein that belongs to the Rho GTPase family, which regulates various cellular functions. Depletion of RND1 expression activates the oncogenic Ras signaling pathway. In this study, we aimed to clarify the clinical significance of RND1 expression in predicting prognosis and to investigate its biological role in human hepatocellular carcinoma (HCC).

Methods

The association between RND1 expression and clinical outcomes in patients with HCC was analyzed in three independent cohorts: 120 cases resected in our hospital; 370 cases in The Cancer Genome Atlas (TCGA); and 242 cases in GSE14520. Gene set enrichment analysis (GSEA) was also conducted. Finally, knockdown experiments were performed using small interfering RNA (siRNA) in vitro.

Results

In all cohorts, RND1 expression was decreased as cancer progressed, and was affected by promoter methylation. In our HCC cases, the 5-year overall survival (OS) and recurrence-free survival of patients with low RND1 expression was significantly poorer than those of patients with high RND1 expression. TCGA and GSE14520 analyses provided similar results for OS. Multivariate analysis indicated that RND1 expression was an independent prognostic factor for OS in all three cohorts. Additionally, GSEA showed an inverse correlation between RND1 expression and the Ras signaling activity. In vitro, knockdown of RND1 expression resulted in significant increases in proliferation, invasion, and chemoresistance to cisplatin in HCC cells.

Conclusions

Reduced RND1 expression in HCC was associated with cancer progression, likely through regulation of the Ras signaling pathway, and may serve as a novel clinical biomarker for predicting prognosis in patients with HCC.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg Today. 2014;44:219–26.CrossRefPubMed
3.
Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87.CrossRefPubMed
4.
Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2009;6:423–2.CrossRefPubMed
5.
Braun AC, Olayioye MA. Rho regulation: DLC proteins in space and time. Cell Signal. 2015;27:1643–51.CrossRefPubMed
6.
Citi S, Spadaro D, Schneider Y, Stutz J, Pulimeno P. Regulation of small GTPases at epithelial cell-cell junctions. Mol Membr Biol. 2011;28:427–44.CrossRefPubMed
7.
8.
Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 2006;16:522–9.CrossRefPubMed
9.
Okada T, Sinha S, Esposito I, et al. The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. Nat Cell Biol. 2015;17:81–94.CrossRefPubMed
10.
Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408–24.CrossRefPubMed
11.
12.
Roessler S, Jia HL, Budhu A, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70:10202–12.CrossRefPubMedPubMedCentral
13.
Roessler S, Long EL, Budhu A, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology. 2012;142:957–966 e912.CrossRefPubMed
14.
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.CrossRefPubMedPubMedCentral
15.
16.
Xiang G, Yi Y, Weiwei H, Weiming W. RND1 is up-regulated in esophageal squamous cell carcinoma and promotes the growth and migration of cancer cells. Tumour Biol. 2016;37:773–9.CrossRefPubMed
17.
Presneau N, Manderson EN, Tonin PN. The quest for a tumor suppressor gene phenotype. Curr Mol Med. 2003;3:605–29.CrossRefPubMed
18.
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–28.CrossRefPubMed
19.
20.
Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours: lessons from the past. Nat Rev Clin Oncol. 2013;10:256–66.CrossRefPubMedPubMedCentral
21.
Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer. 2001;91:1479–86.CrossRefPubMed
22.
Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma. Surg Today. 2015;45:1513–20.CrossRefPubMed
23.
Hsu HC, Wu TT, Wu MZ, Sheu JC, Lee CS, Chen DS. Tumor invasiveness and prognosis in resected hepatocellular carcinoma. clinical and pathogenetic implications. Cancer. 1988;61:2095–9.CrossRefPubMed
24.
Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by Ras and Myc oncogenes in a reconstituted organ. Cell. 1989;56:917–30.CrossRefPubMed
25.
Hipfner DR, Cohen SM. Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol. 2004;5:805–15.CrossRefPubMed
26.
Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol. 2004;14:105–14.CrossRefPubMed
27.
28.
Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA, Wu J. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol. 2011;55:838–45.CrossRefPubMedPubMedCentral
Metadata
Title
Attenuated RND1 Expression Confers Malignant Phenotype and Predicts Poor Prognosis in Hepatocellular Carcinoma
Authors
Hisateru Komatsu, MD
Tomohiro Iguchi, MD, PhD
Takaaki Masuda, MD, PhD
Hidenari Hirata, MD
Masami Ueda, MD
Shinya Kidogami, MD
Yushi Ogawa, MD
Kuniaki Sato, MD
Qingjiang Hu, MD
Sho Nambara, MD
Tomoko Saito, MD
Shotaro Sakimura, MD
Ryutaro Uchi, MD
Shuhei Ito, MD, PhD
Hidetoshi Eguchi, MD, PhD
Keishi Sugimachi, MD, PhD
Hidetoshi Eguchi, MD, PhD
Yuichiro Doki, MD, PhD
Masaki Mori, MD, PhD
Koshi Mimori, MD, PhD
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 3/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5573-9

Other articles of this Issue 3/2017

Annals of Surgical Oncology 3/2017 Go to the issue

Gastrointestinal Oncology

The Preoperative Frailty Versus Inflammation-Based Prognostic Score: Which is Better as an Objective Predictor for Gastric Cancer Patients 80 Years and Older?

Urologic Oncology

Prognostic Impact of Renin-Angiotensin Inhibitors in Patients with Bladder Cancer Undergoing Radical Cystectomy

Neuro-Oncology

Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival

Colorectal Cancer

Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer

Breast Oncology

Extending ACOSOG Z0011 to Encompass Mastectomy: What Happens Without RT?

Breast Oncology

Axillary Ultrasound Before Neoadjuvant Chemotherapy for Breast Cancer: Don’t Discount the Benefits Yet!